Overview

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Status:
Recruiting
Trial end date:
2023-07-17
Target enrollment:
Participant gender:
Summary
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
LY3298176
Tirzepatide